Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Related Articles by Review for PubMed (Select 22825690)

1.

Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60. No abstract available.

PMID:
22825690
2.

Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.

McCormack PL.

Drugs. 2013 Sep;73(13):1491-502. doi: 10.1007/s40265-013-0109-0. Review.

PMID:
23982598
3.

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

Smith MB, Reardon J, Olson EM.

Drugs Today (Barc). 2012 Nov;48(11):713-22. doi: 10.1358/dot.2012.48.11.1885879. Review.

4.

What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

Gourmelon C, Frenel JS, Campone M.

Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167. Review.

PMID:
22316367
5.
6.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
7.

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.

Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 Nov 1;20(21):5359-64. doi: 10.1158/1078-0432.CCR-14-1268. Epub 2014 Sep 9. Review.

PMID:
25204553
8.

Trastuzumab/chemotherapy combinations in metastatic breast cancer.

Ligibel JA, Winer EP.

Semin Oncol. 2002 Jun;29(3 Suppl 11):38-43. Review.

PMID:
12138396
9.

[Pertuzumab. Dual strategy for the first-line treatment of metastatic HER2-positive breast cancer].

Bruhn C.

Med Monatsschr Pharm. 2013 Jun;36(6):210-4. Review. German. No abstract available.

PMID:
23814981
10.

Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient.

Freedman RA, Muss HB.

J Geriatr Oncol. 2014 Jan;5(1):2-7. doi: 10.1016/j.jgo.2013.10.001. Epub 2013 Oct 30. Review.

PMID:
24484711
11.

Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.

Metzger-Filho O, Vora T, Awada A.

Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S31-9. doi: 10.1517/13543781003730135. Review.

PMID:
20374028
12.

HER2 overexpressing metastatic breast cancer.

Spigel DR, Burstein HJ.

Curr Treat Options Oncol. 2002 Apr;3(2):163-74. Review.

PMID:
12057079
14.

Overcoming treatment challenges in advanced breast cancer.

Harkins B, Geyer CE Jr.

Semin Oncol Nurs. 2007 Nov;23(4 Suppl 2):S10-6. doi: 10.1016/j.soncn.2007.10.003. Review.

PMID:
18054677
15.

HERe-2 stay: the continuing importance of translational research in breast cancer.

Sledge GW Jr.

J Natl Cancer Inst. 2004 May 19;96(10):725-7. Review. No abstract available.

16.

[Indications and limitations of primary systemic therapy for operable breast cancer].

Yamamoto N, Suzuki M, Tanabe N.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:500-6. Review. Japanese. No abstract available.

PMID:
17682201
17.

Lapatinib in breast cancer: clinical experiences and future perspectives.

Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S72-9. doi: 10.1016/S0305-7372(10)70024-4. Review.

PMID:
21129615
18.

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N.

Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Review.

19.

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

Khasraw M, Bell R.

Expert Rev Anticancer Ther. 2012 Aug;12(8):1005-13. doi: 10.1586/era.12.62. Review.

PMID:
23030220
20.

[Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].

Galligioni E.

Tumori. 2001 Jan-Feb;87(1 Suppl 2):S1-9. Review. Italian. No abstract available.

PMID:
11357871
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk